[
    [
        {
            "time": "2018-01-02",
            "original_text": "Novartis Expands Presence in Gene Therapy With Acquisition",
            "features": {
                "keywords": [
                    "Novartis",
                    "Expands",
                    "Gene Therapy",
                    "Acquisition"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Top Analyst Reports for PayPal, Comcast & Novartis",
            "features": {
                "keywords": [
                    "Analyst Reports",
                    "PayPal",
                    "Comcast",
                    "Novartis"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "technology",
                    "media"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Analyst Report: Novartis AG",
            "features": {
                "keywords": [
                    "Analyst Report",
                    "Novartis AG"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Eli Lilly",
                    "Merck",
                    "Pfizer",
                    "Novartis",
                    "AstraZeneca",
                    "J&J"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of AimovigÂ® (erenumab) compared with topiramate in migraine prevention",
            "features": {
                "keywords": [
                    "Novartis",
                    "Phase IV",
                    "Aimovig",
                    "erenumab",
                    "topiramate",
                    "migraine prevention"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]